Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors
Lo scopo di questo studio internazionale è quello di cercare di prevedere quali tra i pazienti che ricevono radioterapia sono più soggetti di altri a riportare effetti collaterali
The 5th REQUITE Annual Consortium Meeting will be held 20-21st June 2017, hosted by Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain. This will be held in conjunction with the International Radiogenomics Consortium annual meeting on 19th June. Many of the researchers involved in the REQUITE project are also part of the Radiogenomics consortium. A good reason to combine both yearly meetings at one moment of the year in the same venue, giving the involved people the opportunity to attend both meetings.
The Radiogenomics Consortium was established in November 2009. The scientific hypothesis underlying the development of the consortium is that a cancer patient's likelihood of developing toxicity to radiation therapy is influenced by common genetic variations, such as single nucleotide polymorphisms (SNPs).
The Consortium members undertake collaborative projects to identify SNPs associated with adverse effects following radiotherapy, share data and samples, perform meta-analyses, and work together to submit research grant applications.
The REQUITE paper "Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement", De Ruysscher D, Defraene G, Ramaekers BL, Lambin P, Briers E, Stobart H, Ward T, Bentzen SM, Van Staa T, Azria D, Rosenstein B, Kerns S, West C has been published in the Green Journal, December 2016 Volume 121, Issue 3, Pages 440–446.
The Green Journal is the Journal of the European SocieTy for Radiotherapy & Oncology.
The 5th REQUITE Annual Consortium Meeting will be held 20-21st June 2017 at Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain www.vhio.net. As in previous years, this will be held in conjunction with the International Radiogenomics Consortium annual meeting on 19th June.